Discounted Cash Flow
Collegium Pharmaceutical, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-94.2m | $-75.5m | — | $-3.88 |
| 2017 | — | $-74.9m (20.5%) | $-68.0m (10.0%) | — | $-2.47 (36.3%) |
| 2018 | $280.4m | $-39.1m (47.7%) | $163.9m (341.0%) | -14.0% | $-1.19 (51.8%) |
| 2019 | $296.7m (5.8%) | $-22.7m (41.9%) | $21.3m (-87.0%) | -7.7% (45.1%) | $-0.68 (42.9%) |
| 2020 | $310.0m (4.5%) | $26.8m (217.7%) | $88.4m (314.1%) | 8.6% (212.7%) | $0.78 (214.7%) |
| 2021 | $276.9m (-10.7%) | $71.5m (167.3%) | $101.6m (15.0%) | 25.8% (199.3%) | $2.05 (162.8%) |
| 2022 | $463.9m (67.6%) | $-25.0m (-135.0%) | $122.6m (20.7%) | -5.4% (-120.9%) | $-0.74 (-136.1%) |
| 2023 | $566.8m (22.2%) | $48.2m (292.6%) | $274.3m (123.7%) | 8.5% (257.7%) | $1.43 (293.2%) |
| 2024 | $631.4m (11.4%) | $69.2m (43.7%) | $203.3m (-25.9%) | 11.0% (29.0%) | $2.14 (49.7%) |
| 2025 | $780.6m (23.6%) | $62.9m (-9.1%) | $327.6m (61.1%) | 8.1% (-26.5%) | $1.98 (-7.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.